Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients.
To assess the value of disease stabilization (SD) as a predictor of survival following chemotherapy, data were analyzed from multicenter clinical trials in small cell lung cancer (SCLC) and ovarian cancer (OC) patients receiving various second-line chemotherapy regimens. In both patient populations, SD (lasting >8 weeks) and partial responses (PR) were associated with a survival benefit versus progressive disease (PD); interestingly, the survival benefit was similar between the two groups (PR and SD). These results suggest that, at least in these populations, SD may represent a potential benefit of chemotherapy and therefore the distinction between SD and PR may not be useful.
Cesano
A
A
SmithKline Beecham Pharmaceuticals, Clinical Research and Development, Collegeville, PA 19426-0989, USA.
Lane
S R
SR
Poulin
R
R
Ross
G
G
Fields
S Z
SZ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality*; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality*; D017239:Paclitaxel / Q000627:therapeutic use; D011379:Prognosis; D016879:Salvage Therapy; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D019772:Topotecan / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D019772:Topotecan; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel